Novo Nordisk (NVO)
(Delayed Data from NYSE)
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
NVO 136.97 +0.09(0.07%)
Will NVO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVO
Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, Uber, Spok Holdings and Willis Lease Finance
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top Research Reports for Microsoft, Novo Nordisk & Uber
Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk
Zacks Investment Ideas feature highlights: Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly
Other News for NVO
Hims & Hers wins Buy at Needham despite recent volatility
Viking Therapeutics: Leaping Ahead In The Weight-Loss Race
Significant Results From Historical Drill Hole Infill Assay Program at Belltopper
CDMO executive says Novo purchase of Catalent may help competition - CTFN
Eli Lilly’s tirzepatide cuts risk of diabetes by 94% in obese patients